HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patrick B Lappin Selected Research

2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- one

3/2014Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
1/2013Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
8/2012Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patrick B Lappin Research Topics

Disease

13Neoplasms (Cancer)
03/2015 - 03/2012
3Lung Neoplasms (Lung Cancer)
07/2015 - 03/2012
3Neoplasm Metastasis (Metastasis)
09/2012 - 03/2012
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2015 - 01/2013
2Adenocarcinoma
03/2014 - 08/2012
2Breast Neoplasms (Breast Cancer)
03/2014 - 09/2012
1Brain Neoplasms (Brain Tumor)
07/2015
1Glioblastoma (Glioblastoma Multiforme)
03/2015
1Body Weight (Weight, Body)
01/2015
1Genomic Instability
01/2015
1Neutropenia
01/2015
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2014
1Choriocarcinoma
03/2014
1Carcinoma (Carcinomatosis)
03/2014
1Urinary Bladder Neoplasms (Bladder Cancer)
03/2014
1Ovarian Neoplasms (Ovarian Cancer)
03/2014
1Colorectal Neoplasms (Colorectal Cancer)
01/2013
1HIV Infections (HIV Infection)
08/2012
1Sudden Infant Death (SID)
08/2012
1Adenoma (Adenomas)
08/2012
1Infections
08/2012
1Hyperplasia
08/2012
1Adenocarcinoma of Lung
08/2012
1Stress Urinary Incontinence
04/2011

Drug/Important Bio-Agent (IBA)

4Pharmaceutical PreparationsIBA
01/2015 - 03/2014
3CrizotinibIBA
03/2015 - 07/2012
3Phosphotransferases (Kinase)IBA
03/2015 - 03/2014
3Biomarkers (Surrogate Marker)IBA
01/2015 - 09/2012
32- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA
03/2014 - 08/2012
2lorlatinibIBA
07/2015 - 03/2015
2Sunitinib (Sutent)FDA Link
06/2014 - 07/2012
2nirogacestatIBA
06/2014 - 09/2012
2Amyloid Precursor Protein Secretases (beta-Secretase)IBA
06/2014 - 09/2012
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2014 - 08/2012
2mirdametinibIBA
03/2014 - 08/2012
1Anaplastic Lymphoma KinaseIBA
07/2015
1Cisplatin (Platino)FDA LinkGeneric
03/2014
1GlucocorticoidsIBA
03/2014
1Proteins (Proteins, Gene)FDA Link
03/2014
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
03/2014
1Macrophage Colony-Stimulating FactorIBA
03/2014
1Sirolimus (Rapamycin)FDA Link
03/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2014
1Cytostatic AgentsIBA
03/2014
1Contrast MediaIBA
01/2013
1Messenger RNA (mRNA)IBA
09/2012
1ElementsIBA
08/2012
1AutoantigensIBA
08/2012
1Cre recombinaseIBA
08/2012
1DNA Transposable Elements (Element, IS)IBA
08/2012
1Angiogenesis InhibitorsIBA
07/2012
1OsteopontinIBA
03/2012
1Carboplatin (JM8)FDA LinkGeneric
03/2012
1ThymidineIBA
03/2012
1Polymethyl Methacrylate (Sol)IBA
04/2011

Therapy/Procedure

4Therapeutics
03/2015 - 03/2012
3Aftercare (After-Treatment)
06/2014 - 09/2012
1Microbubbles
06/2014
1Precision Medicine
03/2014
1Microspheres (Microsphere)
04/2011